Trial of cannabidiol for drug-resistant seizures in the dravet syndrome

New England Journal of Medicine

Volumn 376, Issue 21, 2017, Pages 2011-2020

  Devinsky, Orrin ^a,j   Cross, J Helen ^b   Laux, Linda ^d   Marsh, Eric ^e   Miller, Ian ^f   Nabbout, Rima ^g   Scheffer, Ingrid E ^h   Thiele, Elizabeth A ⁱ   Wright, Stephen ^c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Porton Down Science Park   (United Kingdom)

^d Ann and Robert H Lurie Children's Hospital of Chicago   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f MIAMI CHILDREN'S HOSPITAL   (United States)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CANNABIDIOL; CLOBAZAM; LEVETIRACETAM; PLACEBO; STIRIPENTOL; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CAREGIVER GLOBAL IMPRESSION OF CHANGE SCALE; CHILD; CONTROLLED STUDY; CONVULSION; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG RESISTANT EPILEPSY; DRUG WITHDRAWAL; EVALUATION AND FOLLOW UP; FATIGUE; FEMALE; FEVER; HUMAN; HYPERTRANSAMINASEMIA; KETOGENIC DIET; LETHARGY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VAGUS NERVE STIMULATION; VOMITING; YOUNG ADULT; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; EPILEPSIES, MYOCLONIC; LIVER; SEIZURES;

ADOLESCENT; ANTICONVULSANTS; CANNABIDIOL; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; EPILEPSIES, MYOCLONIC; FATIGUE; FEMALE; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; SEIZURES;

EID: 85019817940     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1611618     Document Type: Article

References (14)

1. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013; 29: 574-7.
2. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175-85.
3. Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Presented at the Marijuana '90 International Conference on Cannabis and Cannabinoids, Kolympari, Crete, July 8-11, 1990.
4. Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften 1978; 65: 174-9.
5. Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J 1986; 69: 14.
6. Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010; 332: 569-77.
7. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatmentresistant epilepsy: an open-label interventional trial. Lancet Neurol 2016; 15: 270-8.
8. Cooper MS, Mcintosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res 2016; 128: 43-7.
9. Devinsky O. Sudden, unexpected death in epilepsy. N Engl J Med 2011; 365: 1801-11.
10. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51: 1069-77.
11. Zadeh WW, Escartin A, Byrnes W, et al. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: a multicentre open-label trial. Seizure 2015; 31: 72-9.
12. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015; 56: 1246-51.
13. Statistical review and evaluation: antiepileptic drugs and suicidality. Silver Spring, MD: Food and Drug Administration, 2008 (http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafety informationforpatientsandproviders/ ucm192556 .pdf).
14. Guidance for industry - suicidal ideation and behavior: prospective assessment of occurrence in clinical trials. Silver Spring, MD: Food and Drug Administration, 2012 (http://www .fda .gov/ downloads/Drugs/. ./ Guidances/ UCM225130 .pdf).